Molecular basis of chemical chaperone effects of N-octyl-β-valienamine on human β-glucosidase in low/neutral pH conditions

Journal of Proteomics and Bioinformatics

Volumn 3, Issue 4, 2010, Pages 104-112

  Jo, Hiroyuki ^a   Yugi, Katsuyuki ^a   Ogawa, Seiichiro ^a   Suzuki, Yoshiyuki ^b   Sakakibara, Yasubumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Binding free energy change; Chemical chaperone; Human glucosidase; Hydrogen bonds; Molecular dynamics; N otyl valienamine(NOV); pKa

Indexed keywords

EID: 77951735525     PISSN: None     EISSN: 0974276X     Source Type: Journal    
DOI: 10.4172/jpb.1000128     Document Type: Article

References (41)

1. Amaral O, Marcao A, Sa Miranda M, Desnick RJ, Grace ME (2000) Gaucher disease: expression and characterization of mild and severe acid β-glucosidase mutations in Portuguese type 1 patients. Eur J Hum Genet 8: 95-102.
2. Bas DC, Rogers DM, Jensen JH (2008) Very fast prediction and rationalization of pKa values for protein-ligand complexes. Proteins 73: 765-783.
3. Berendsen HJ, Hayward S (2000) Collective protein dynamics in relation to function. Curr Opin Struct Biol 10: 165-169.
4. Boustany RM, Qian WH, Suzuki K (1993) Mutations in acid β-galactosidase cause GM1-gangliosidosis in American patients. Am J Hum Genet 53: 881-888.
5. Brandsdal BO, Smalas AO, Aqvist J (2006) Free energy calculations show that acidic P1 variants undergo large pKa shifts upon binding to trypsin. Proteins 64: 740-748.
6. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
7. Case DA, Darden TA, Cheatham TE III, Simmerling CL, Wang J, et al. (2006) AMBER 9: University of California, San Francisco.
8. Creveld LD, Amadei A, van Schaik RC, Pepermans HA, de Vlieg J, et al. (1998) Identification of functional and unfolding motions of cutinase as obtained from molecular dynamics computer simulations. Proteins 33: 253-264.
9. Davies JP, Eng CM, Hill JA, Malcolm S, MacDermot K, et al. (1996) Fabry disease: fourteen α-galactosidase A mutations in unrelated families from the United Kingdom and other European countries. Eur J Hum Genet 4: 219-224.
10. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, et al. (1995) A Smooth Particle Mesh Ewald Method. J Chem Phys 103: 8577-8593.
11. Fabrega S, Durand P, Codogno P, Bauvy C, Delomenie C, et al. (2000) Human glucocerebrosidase: heterologous expression of active site mutants in murine null cells. Glycobiology 10: 1217-1224.
12. Fan JQ, Ishii S (2007) Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J 274: 4962-4971.
13. Fan JQ, Ishii S, Asano N, Suzuki Y (1999) Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5: 112-115.
14. Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human á-galactosidase. J Mol Biol 337: 319-335.
15. Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, et al. (2007) Mutant á-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 406: 285-295.
16. Joshi MD, Sidhu G, Pot I, Brayer GD, Withers SG, et al. (2000) Hydrogen bonding and catalysis: a novel explanation for how a single amino acid substitution can change the pH optimum of a glycosidase. J Mol Biol 299: 255-279.
17. Kazmirski SL, Li A, Daggett V (1999) Analysis methods for comparison of multiple molecular dynamics trajectories: applications to protein unfolding pathways and denatured ensembles. J Mol Biol 290: 283-304.
18. Kieseritzky G, Morra G, Knapp EW (2006) Stability and fluctuations of amide hydrogen bonds in a bacterial cytochrome c: a molecular dynamics study. J Biol Inorg Chem 11: 26-40.
19. Kitao A, Go N (1999) Investigating protein dynamics in collective coordinate space. Curr Opin Struct Biol 9: 164-169.
20. Leandro P, Gomes CM (2008) Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. Mini Rev Med Chem 8: 901-911.
21. Lei K, Ninomiya H, Suzuki M, Inoue T, Sawa M, et al. (2007) Enzyme enhancement activity of N-octyl-β-valienamine on β-glucosidase mutants associated with Gaucher disease. Biochim Biophys Acta 1772: 587-596.
22. Li H, Robertson AD, Jensen JH (2005) Very fast empirical prediction and rationalization of protein pKa values. Proteins 61: 704-721.
23. Lieberman RL, Wustman BA, Huertas P, Powe AC Jr, Pine CW, et al. (2007) Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3: 101-107.
24. Lin H, Sugimoto Y, Ohsaki Y, Ninomiya H, Oka A, et al. (2004) N-octyl-β- valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim Biophys Acta 1689: 219-228.
25. Matsuda J, Suzuki O, Oshima A, Yamamoto Y, Noguchi A, et al. (2003) Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc Natl Acad Sci USA 100: 15912-15917.
26. Miao S, McCarter JD, Grace ME, Grabowski GA, Aebersold R, et al. (1994) Identification of Glu340 as the active-site nucleophile in human glucocerebrosidase by use of electrospray tandem mass spectrometry. J Biol Chem 269: 10975-10978.
27. Ogawa S, Ashiura M, Uchida C, Watanabe S, Yamazaki C, et al. (1996) Synthesis of potent β-D-glucocerebrosidase inhibitors: N-alkyl-β-valienamines. Bioorg Med Chem Lett 6: 929-932.
28. Ogawa S, Kobayashi Y, Kabayama K, Jimbo M, Inokuchi J (1998) Chemical modification of betaglucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivatives. Bioorg Med Chem 6: 1955-1962.
29. Okumiya T, Ishii S, Kase R, Kamei S, Sakuraba H, et al. (1995a) β-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins. Hum Genet 95: 557-561.
30. Okumiya T, Ishii S, Takenaka T, Kase R, Kamei S, et al. (1995b) Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease. Biochem Biophys Res Commun 214: 1219-1224.
31. Perlmutter DH (2002) Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 52: 832-836.
32. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.
33. Premkumar L, Sawkar AR, Boldin-Adamsky S, Toker L, Silman I, et al. (2005) X-ray structure of human acid-β-glucosidase covalently bound to conduritol- B-epoxide. Implications for Gaucher disease. J Biol Chem 280: 23815-23819.
34. Rodziewicz-Motowidlo S, Wahlbom M, Wang X, Lagiewka J, Janowski R, et al. (2006) Checking the conformational stability of cystatin C and its L68Q variant by molecular dynamics studies: why is the L68Q variant amyloidogenic? J Struct Biol 154: 68-78.
35. Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23: 327-341.
36. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, et al. (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99: 15428-15433.
37. Suzuki Y (2006) β-galactosidase deficiency: an approach to chaperone therapy. J Inherit Metab Dis 29: 471-476.
38. Suzuki Y (2008) Chemical chaperone therapy for GM1-gangliosidosis. Cell Mol Life Sci 65: 351-353.
39. Suzuki Y, Ichinomiya S, Kurosawa M, Ohkubo M, Watanabe H, et al. (2007) Chemical chaperone therapy: clinical effect in murine GM1-gangliosidosis. Ann Neurol 62: 671-675.
40. Swanson JM, Henchman RH, McCammon JA (2004) Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. Biophys J 86: 67-74.
41. Yam GH, Zuber C, Roth J (2005) A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J 19: 12-18.